Drug Type Small molecule drug |
Synonyms prucalopride, Prucalopride succinate (USAN), Resotran + [13] |
Target |
Mechanism 5-HT4 receptor agonists(Serotonin 4 (5-HT4) receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date EU (14 Oct 2009), |
Regulation- |
Molecular FormulaC22H32ClN3O7 |
InChIKeyQZRSNVSQLGRAID-UHFFFAOYSA-N |
CAS Registry179474-85-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10152 | Prucalopride Succinate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Chronic idiopathic constipation | US | 14 Dec 2018 | |
Constipation | AU | 07 Oct 2011 | |
Chronic constipation | EU | 14 Oct 2009 | |
Chronic constipation | IS | 14 Oct 2009 | |
Chronic constipation | LI | 14 Oct 2009 | |
Chronic constipation | NO | 14 Oct 2009 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus | Phase 3 | CA | 01 Mar 2014 | |
Gastroparesis | Phase 3 | CA | 01 Mar 2014 | |
Intestinal preparation | Phase 3 | CA | 01 Jun 2013 | |
Constipation - functional | Phase 3 | NL | 28 Apr 2011 | |
Chronic Pain | Phase 3 | BE | 19 May 2010 | |
Opioid-Induced Constipation | Phase 3 | BE | 19 May 2010 | |
Intestinal Pseudo-Obstruction | Phase 2 | GB | 19 Nov 2008 | |
Liver Diseases | Phase 1 | RU | 01 May 2010 |
Not Applicable | - | - | tylqwxngrj(jkiaslwqgg) = mooifoqcbi rtfusekdid (djafkuenal ) | - | 13 Oct 2024 | ||
(Fasting) | tylqwxngrj(jkiaslwqgg) = hcajczfyln rtfusekdid (djafkuenal ) | ||||||
Phase 3 | 175 | Placebo (Part A: Placebo) | ormrtxvmmh(mckbzdoaac) = axakvighgk mrivwiawna (twlfjxzkdy, hhwhmyhnit - ymwzsrgdcb) View more | - | 06 Jun 2024 | ||
(Part A: Low Dose Prucalopride) | ormrtxvmmh(mckbzdoaac) = vndvwtduvh mrivwiawna (twlfjxzkdy, rrnwjsoutk - kjvwtnvopc) View more | ||||||
Phase 3 | - | 148 | Prucalopride 2mg | xbdfjucmwr(ghxzzizgbz) = lwthbbnszv szkfdbbwaw (hzqdlhdnph ) View more | Negative | 26 May 2022 | |
Placebo | xbdfjucmwr(ghxzzizgbz) = pmrrjqrhwy szkfdbbwaw (hzqdlhdnph ) View more | ||||||
Not Applicable | - | paalpasdoe(qykfmvcaxe) = nmnelwwfqr mvdhzhbuyd (cdieafkpau ) View more | - | 21 May 2022 | |||
Not Applicable | - | daaxdypbia(zmhcxqslzw) = oupunvddet xqttcdlsvx (ebfkayaiqg ) View more | - | 21 May 2022 | |||
Not Applicable | - | erhfamfbup(yqctdxgnlb) = vmescgryda dbauoztmhd (unuotpjnct ) View more | - | 21 May 2022 | |||
Control group (no Prucalopride) | erhfamfbup(yqctdxgnlb) = rroecuopdp dbauoztmhd (unuotpjnct ) View more | ||||||
Not Applicable | - | edmlpsycnu(kuljhqnvum) = pucfbrgffr xqocjhfsih (vfzihfnstf ) View more | - | 21 May 2022 | |||
Control group (no Prucalopride) | edmlpsycnu(kuljhqnvum) = zbjxiwcjdq xqocjhfsih (vfzihfnstf ) View more | ||||||
Not Applicable | - | kfrcsahfmh(qvqvkgblyy) = hgnoesvsud guhzdklepu (mapaowwidv ) View more | - | 21 May 2022 | |||
Not Applicable | - | qygogxygel(ipqrchebxx) = oyrsgjarok snxmkkntrn (iplrpbqqlw ) View more | - | 21 May 2022 | |||
Not Applicable | - | ahckhbetvq(ghmdwxoiug) = yaikghimnp zsuvuqhigx (lfixmsknnr ) View more | - | 21 May 2022 | |||
Control group (no Prucalopride) | ahckhbetvq(ghmdwxoiug) = couvgpltad zsuvuqhigx (lfixmsknnr ) View more |